NovoSeven, also known by its generic name, recombinant activated Factor VII (rFVIIa), is a medication used in the treatment of bleeding episodes in patients with hemophilia A or B who have developed inhibitors against coagulation factors VIII or IX. It is also used for the treatment of bleeding in patients with congenital Factor VII deficiency and in those undergoing surgery or invasive procedures who have hemophilia. NovoSeven works by aiding the blood clotting process, thereby helping to control bleeding. It is administered via injection, and its use must be closely monitored by healthcare professionals due to the potential for serious side effects, including the risk of thrombotic events. NovoSeven has been a significant advancement in the management of bleeding disorders, providing an option for patients who might otherwise have limited treatments available.